Introduction
In conventional insulin pump therapy for type 1 diabetes mellitus (T1DM), basal insulin is administered to keep glycemia in the normal range for fasting conditions and bolus insulin is administered to correct for hyperglycemia and to compensate for the influence of meals. Generally, the bolus insulin calculation is based on the subject's insulin-to-carbohydrate ratio, correction factor, and insulin on board. 1, 2 There are several steps to determine the basal insulin rate. 3, 4 The first step is to determine the total daily dose (TDD):
where W is the subject's mass and K is a subject-specific constant. If the units of W are in kilograms, the range of K is typically 0.5 to 2.0 U/kg. The basal insulin requirement is approximately 50% of TDD, so the basic basal rate (U/h) should be
Insulin sensitivity changes throughout the day due to circadian variation of hormone levels. During a single 24 h cycle, basal insulin requirements are relatively high during the early morning, decreasing during the daytime, and further declining in the middle of the night. Relative a nominal basal rate from 10:00 am to midnight, the basal rate would be 50% less between midnight and 4:00 am and 50% more in the early morning between 4:00 am and 10:00 am. Figure 1 shows insulin delivery with basal-bolus therapy; a 24 h period is divided into three segments corresponding to the main trends in insulin sensitivity. The transition times are flexible and could be subject dependent.
In conventional basal therapy, the basal rate is fixed in each segment. Since 2005, continuous glucose monitoring (CGM) technology has improved significantly, and the reliable duration of in vivo sensors continue to increase. 5, 6 Frequent CGM measurements provide the possibility of predicting hypoglycemic and hyperglycemic events and suggesting corrective actions.
Using a linear prediction scheme, the glycemia can be predicted as a function of the current glucose concentration and its rate of change (ROC). Furthermore, a new basal rate is suggested using the predicted glucose concentration: if a hyperglycemic event is predicted, the basal rate could be increased, and if a hypoglycemia event is predicted, the basal rate could be decreased. Therefore, an adaptive basal therapy based on the glucose value and its ROC is suggested in this paper. Taking glucose and its ROC as the axes, a two-dimensional plane is divided into nine zones and a corresponding basal multiplier is associated with each zone. For example, a zero multiplier indicates a recommendation to suspend insulin delivery, and a multiplier of two corresponds to doubling the basal rate.
The adaptive basal therapy is a two-step method. An initial basal profile is designed by using existing methods. Based on current CGM reading and its ROC, the basal rate is adapted using a gain multiplier. For simplicity and robustness, the basal rate is adjusted every 30 min, so it can be managed automatically or manually.
The simplicity of the proposed approach is advantageous for rapid implementation because it does not require a subject model, unlike some closed-loop control algorithms. As a rule-based methodology, the adaptive basal therapy has some similarities with the fuzzy logic methodology. 7 However, unlike the fuzzy logic methodology, membership functions are not used in the proposed therapy, so the adaptive basal therapy is simpler to implement and easier to understand. The proposed method is evaluated on 20 in silico subjects in the Food and Drug Administration (FDA)-approved UVa/Padova simulator. 8 The results indicate that the basal adaptation can improve the control performance for all subjects. Using advisory mode evaluation, 9 the proposed method is further tested on retrospective clinical data from subjects with T1DM. 
Adaptive Basal Therapy

Basal Gain Mosaic
According to the Diabetes Control and Complications Trial Research Group, 10 hyperglycemia is defined as postprandial blood glucose (BG) concentration greater than 180 mg/dl. The hypoglycemia definition varies according to the research context and the subject's symptoms. In this work, a value of 60 mg/dl is selected as the threshold, and deviations below this value are termed significant hypoglycemia. Accordingly, BG concentrations between 60 and 180 mg/dl are considered to be within the safe range for T1DM in this paper. The objective of updating the basal rate is to keep glucose concentration within the safe range.
If the BG concentration at step k, G(k), and its ROC, Gʼ(k), are known, the simplest prediction for glucose at step k + l, where l denotes the number of prediction steps, is as follows: ,
where Dt is the sample time. Therefore, the current glucose value and its ROC can be used to modify the basal rate to achieve tighter glycemic control. Hence the basal rate can be described as a function of the value and ROC of BG.
The frequency of changes to the basal rate is governed by two factors: (1) convenience to the user and (2) consideration of delayed insulin action. The latter aspect addresses the fact that insulin Lispro achieves peak levels 30 to 90 min after administration. 11 If the frequency of changes to the basal rate is too slow, the improvement will be ineffective. The basal rate will be updated every 30 min to balance these two factors.
The main idea of this work is illustrated in Figure 2 , which shows the basal gain mosaic. The mosaic consists of nine zones (A-I), and five predefined gains are presented for the insulin basal rate multiplier. The key scenarios for choosing the basal gains are as follows:
• Case 1: if BG is in the hypoglycemic range (e.g., BG = 50 mg/dl) or BG is normal with a significant negative ROC (e.g., BG = 100 mg/dl and ROC = -2 mg/[dl‧min]), then the basal gain multiplier should be chosen as zero, which indicates a recommendation to suspend insulin delivery, i.e., zone A.
• Case 2: if BG is normal and ROC has a small absolute value, i.e., zone E (e.g., BG = 110 mg/dl and The divisions for BG and ROC are now described. Continuous glucose monitoring sensors are prone to measurement noise and drift; for example, the numerical errors of the DexCom STS (DexCom, San Diego, CA) sensor are approximately 30%. 12 To improve the robustness of the proposed method in the presence of measurement noise, the hypoglycemia threshold for the BG is chosen as 80 mg/dl. The actual BG for a CGM value of 80 mg/dl might be as low as 56 mg/dl; therefore, CGM readings larger than 80 mg/dl indicate the real BG concentrations are approximately above the hypoglycemia threshold (60 mg/dl). On the other hand, 120 and 180 mg/dl are considered the hyperglycemia thresholds under fasting and postprandial conditions, respectively. 10 Therefore, a moderate value, 140 mg/dl, is chosen as the hyperglycemia threshold in this work.
The division of ROC depends on the current value of BG. If the glucose value is between 80 and 140 mg/dl, the time when the glucose curve will cross the threshold from one zone to another is estimated using Equation ( 
Estimating Rate of Change
To use the basal gain mosaic, the value of the ROC should first be estimated. The simplest way to do this at step k is as follows: ,
where T > 0 is the sample time and is set to be 5 min in this work, in accordance with the DexCom STS. 12 However, the preceding scheme is very sensitive to measurement noise. To improve the robustness, a threepoint (current and two previous samples) backward difference was used to estimate ROC in the literature. 13 Because the basal rate is updated every 30 min and the sample time is 5 min, there are six new samples available for estimation of the ROC; therefore, a weighted average scheme is used in this work. Thus ,
where 0 ≤ l < 1 is the forgetting factor. 14 The forgetting factor is used to balance the contributions of current data and historical data. If the forgetting factor is zero, only the current data are used; if the forgetting factor is unity, the current data and historical data are given the same weight. In general, a larger forgetting factor indicates increased robustness to measurement noise but a decrease in accuracy for estimating the real-time ROC. Equation (5) reduces to Equation (4) if l = 0. Hence the estimation of ROC can be considered a function of l. Furthermore, the prediction of the glucose measurement 30 min later can be expressed aŝ (6) This prediction scheme is linear. The optimal l is defined asˆ (7) Note that l * is related to the sensor type and the subject; even for the same sensor and subject, l * may vary from day to day. The following results demonstrate that even a fixed, nonoptimal l can improve the control performance, validating the robustness of the proposed method.
Summary of Adaptive Basal Therapy
The procedure to implement the proposed scheme is summarized in the following algorithm:
Algorithm (flowchart of adaptive basal therapy) 1. Initialization: determine the optimal basal rate using standard methods.
2. Use the available glucose measurement to get l * based on Equation (7). In step 2, l * is determined by solving the optimization problem in Equation (7); l * is fixed at 0.5 in this work for simplicity.
In Silico Evaluation
The proposed therapy was tested on 10 adult subjects, adults 1-10, and ten adolescent subjects, adolescents 1-10, in the FDA-approved UVa/Padova diabetes simulator. Because a virtual CGM sensor was included in the UVa/Padova simulator to approximate the real measurement noise, there are two sets of values for glucose: CGM readings and BG concentrations. Only CGM reading is available for control design, while the BG value is used to evaluate the designed controller in this work. All these subjects followed a protocol of three meals: 40 g of carbohydrates at 7:00 am, 75 g at noon, and 60 g at 6:00 pm. A matching insulin bolus and an optimal basal rate were provided in the simulator for each in silico subject; this therapy is called the fixed basal therapy, where the bolus is based on perfect meal size estimation and the basal is optimized for each in silico subject. If the same bolus is dosed and the basal rate is updated based on the basal gain mosaic, this therapy is called the adaptive basal therapy. The control performances for fixed and adaptive basal therapies are compared in this section.
Optimal Forgetting Factor
The fixed basal therapy was implemented on each subject for one day, and the CGM data were used to calculate the optimal forgetting factor for each subject based on Equation (7). The optimization problem in Equation (7) was solved with the command "fminbnd" in MATLAB ® (The MathWorks Inc., Natick, MA). The optimal forgetting factors for 20 subjects are given in Table 1 . The best way to use the adaptive basal therapy is to find the optimal forgetting factor for the corresponding subject. However, to simplify the design procedure and validate the robustness of the proposed scheme, a median value of l = 0.5 is used for all subjects.
From Table 1 , the optimal forgetting factor for adolescent 4 is 0.51, and that for adult 1 is 0. The prediction results for these subjects are given in Figure 3 for performance evaluation. For instance, the prediction for 60 min is based on the CGM values from 0 to 30 min. It is evident that the prediction is not good even though the optimal forgetting factor is used. There are two possible reasons for the bad performance:
• Due to measurement noise, the CGM value is far from the BG value.
• The linear prediction scheme is too simple to describe the actual glucose trend.
The control results as shown demonstrate that the adaptive basal improved the control performance even though a simple prediction scheme was utilized. 
In Silico Evaluation
The control performances under fixed and adaptive basal therapies are compared in Table 2 . In terms of time percentage within the safe range, the adaptive basal therapy improved the control performance in 90% of the cases for adults and in 100% of the cases for adolescents. The average percentages in the safe range for all adults are 86.7% under the fixed basal therapy and 95.1% under the adaptive basal therapy. Correspondingly, the percentages for adolescents are 63.6% and 76.1%, respectively. In both age groups, the adaptive basal improved the control performance.
To evaluate the risk level of glucose concentration, indices from the literature 15 are employed. For a given glucose concentration value G in units of mg/dl, these risk indices are defined aŝ , where HR is the high blood glucose index (BGI) and LR is the low BGI, respectively. Furthermore, HR + LR is defined as the BGI. Low BGI suggests minor risk of hyperglycemia and hypoglycemia. Given multiple CGM readings, the value of BGI is computed as the means of all BGI. In terms of a smaller BGI, the adaptive basal therapy improved the control performance in 90% of the cases for adults and in 100% of the cases for adolescents. The average BGI values for adults were 3.2 under the fixed basal therapy and 1.7 under the adaptive basal therapy; these values for adolescents were 5.9 and 3.4, respectively. These indices validate that the adaptive basal scheme improved glucose control. Furthermore, the differences between these results are statistically significant with p values less than 0.05. 16 The p values for the time percentage in the safe range and BGI in the adult subjects were 0.0160 and 0.0361. Similarly, the p values in adolescent subjects were 0.0145 and 0.0112.
The glucose levels of adult 2 under both therapies are shown in Figure 4A , and the basal gain is displayed in Figure 4B . Figure 4 illustrates how the proposed scheme avoided hypoglycemia. Control results for adolescent 9 are given in Figure 5 to show how hyperglycemia was avoided.
Magni and coworkers 17 introduced a tool for evaluating the quality of closed-loop glucose control on a group of subjects, termed as control-variability grid analysis. The control-variability grid analysis results for 20 subjects under adaptive and fixed basal therapies are compared in Figure 6 . Compared to the fixed basal therapy, the adaptive basal therapy increases the percentage in A zone and decreases the percentage in C zone, which indicates better performance.
To further evaluate the robustness of the proposed algorithm, we consider a practical scenario where meal size was poorly estimated by the subject. This will result with either over-or under-size insulin bolus. Both the adult average subject and the adolescent average subject in the UVa/Padova simulator were compared under fixed and adaptive basal therapies, respectively. As shown in Table 3 , the adaptive basal therapy is superior to the fixed basal one in all cases.
Clinical Advisory Mode Evaluation
After the simulation study and before implementation of the proposed method in clinic, it is desirable to evaluate the algorithm on retrospective clinical data. Hence advisory mode evaluation, or advisory mode control, 9, 18 Data were collected from two adult subjects with T1DM wearing continuous glucose sensors (DexCom STS, San Diego CA). Five-minute glucose sampling produced 288 measurements per day. The CGM readings in 24 and 12 h periods for two subjects, respectively, were used to evaluate the adaptive basal therapy. Subject 1 is an 83 kg, 173.5 cm male, and subject 2 is a 58 kg, 173 cm male.
The advisory mode evaluation results for subject 1 are shown in Figure 8 . Control actions in terms of basal gain change start before hypoglycemic and hyperglycemic events occur in most cases. For example, the suggested basal insulin increases at 3:00 pm in advance of a hyperglycemic event. Hyperglycemia can be avoided or at least mitigated using the adaptive basal therapy. Similarly, the advisory mode evaluation results for subject 2 are shown in Figure 9 . From 7:15 am, the glucose level decreased. To avoid hypoglycemia, a meal was consumed at 8:04 am. For the adaptive basal case, the basal insulin was suspended after 7:15 am; therefore, the need for a correction meal may have been avoided. For both subjects, the total basal insulin amount for each algorithm is similar. Therefore, the proposed therapy could improve closed-loop performance by changing the distribution, not the amount, of basal insulin.
Summary
The simulation study showed that CGM-based basal adaptation can improve control performance of basal therapy. The advisory mode evaluation study with actual clinical data also showed the feasibility of the proposed method. The adaptive scheme provides the flexibility to account for insulin sensitivity variations due to stress and physical activities.
Because of its simplicity, the adaptive basal therapy could be implemented on microchip in future algorithmdriven insulin pumps. The basal gain mosaic could be used as a guideline for patients and physicians to adjust basal rate. In future studies, this method will be validated in vivo for both "normal" days and days with abnormal insulin sensitivities due to stress and/or exercise. A CGM values and hyper-and hypoglycemic thresholds and B original basal insulin and suggested basal insulin. The total original basal insulin is 39.4 U, and the total suggested basal insulin is 34.6 U. The following meals and matching boluses were given: at 10:12 am, a meal with 61 g carbohydrates and 10.9 U of bolus insulin were consumed; at 1:02 pm, a meal with 60 g carbohydrates was consumed without bolus; at 3:42 pm, 10 U of bolus was injected; and at 10:21 pm, a meal with 60 g carbohydrates and 6.8 U of bolus were consumed. 
